期刊文献+

幼年特发性关节炎患儿基质金属蛋白酶及细胞因子的改变及意义 被引量:6

Changes of matrix metalloproteinase and cytokines and its clinical significance in children with juvenile idiopathic arthritis
原文传递
导出
摘要 目的探讨幼年特发性关节炎(JIA)多关节型患儿血清及关节液基质金属蛋白酶(MMP)-1、MMP-3、金属蛋白酶抑制剂(TIMP)-1、白细胞介素(IL)-1、肿瘤坏死因子(TNF)-α,转化生长因子(TGF)-β水平的变化及临床意义。方法酶联免疫吸附试验(ELISA)检测32例多关节型JIA患儿及28例对照组(外伤性关节炎患儿)血清及关节液中MMP-1、MMP-3、TIMP-1、IL-1、TNF-α、TGF-β的水平。同时检测血白细胞计数、C反应蛋白(CRP)、红细胞沉降率(ESR)及类风湿因子(RF)水平。统计学方法采用两个独立样本的t检验及Pearson直线相关分析。结果①JIA组血清MMP-1、MMP-3、IL-1、TNF—α水平分别为(158±67)ng/ml、(212±89)n咖l、(39±19)pg/ml、(26±10)pg/ml,明显高于对照组(P均〈0.05),MMP-3/TIMP-1为0.86±0.32,亦较对照组升高(P〈0.05),TIMP-1、TGF-β水平分别为(248±88)、(17±9)ng/ml,明显低于对照组(P均〈0.05);血清MMP-3、MMP-3/TIMP-1与白细胞计数、CRP、ESR呈正相关(JP均〈0.05)。②JIA组关节液MMP-1、MMP-3、IL-1、TNF-α水平分别为(216±78)ng/m1、(766±291)ng/ml、(56±21)pg/ml、(36±14)pg/ml,明显高于对照组(P均〈0.05),MMP-3/TIMP-1为2.68±0.89,亦较对照组明显升高(P〈0.05),TIMP-1、TGF—β水平分别为(286±88)、(12±4)ng/ml,明显低于对照组(P均〈0.05)。③JIA组关节液MMP-1、MMP-3、TIMP-1、IL-1、TNF-α水平明显高于其血清水平(P均〈0.05),TGF.B水平则明显低于其血清水平(P〈0.05)。结论血清及关节液中MMP-1、MMP-3、IL-1、TNF—d水平升高,TIMP-1水平降低,参与了JIA多关节型的发病过程,TGF-β水平降低,在其发病中可能起保护作用。血清MMP-3/TIMP-1比值与JIA炎性指标呈正相关,有助于判断病情活动性。 Objective The purpose of the study was to investigate the changes and clinical signific- ance of matrix metalloproteinase (MMP)-1, MMP-3, tissue inhibitor of metalloproteinase (TIMP), interleukin (IL)-1, tuhmr necrosis factor (TNF)-α and transforming growth factor(TGF)-β in juvenile idiopathic arthritis (JIA). Methods Thirty-two JIA subjects and 28 controls (traumatic arthritis patients) were included into this study. The MMP-1, MMP-3, TIMP, IL-1, TNF-α and TGF-β level in the serum and synovia were assessed by ELISA. The WBC count, the level of CRP, ESR, RF were also detected. Independent t-test and Pearson's analysis were adopted for data analysis. Results ① The level of MMP-1, MMP-3, IL-1 and TNF-α in the serum was (158±67) ng/ml, (212±89) ng/ml, (39±19) pg/ml, (26±10) pg/ml respectively, which was significantly higher than that of the control group (all P〈O.05); the ratio of MMP-3/TIMP-1 (0.86±0.32) was higher in the study group than that of the control group (P〈0.05),while the value of TIMP-1, TGF-β was (248±88), (17±9) ng/ml respectively, which was lower than that of the'control group (P〈0.05). The value of seral MMP-3, MMP-3/TIMP-1 was positively correlated with that of WBC, CRP, ESR in the JIA group (all P〈0.05). ② The value of MMP-1, MMP-3, IL-1 and TNF-α in the synovia was (216±78) ng/ml, (766±291) ng/ml, (56±21) pg/ml, (36±14) pg/ml respectively, which was higher than that of the control group (all P〈0.05); the ratio of MMP-3/TIMP-1 (2.68±0.89) was higher than that of the control group (P〈0.05), while the value of TIMP-1, TGF-β was (286±88) ng/ml, (12±4) ng/ml respectively, which was lower than that of the control group (all P〈0.05). ③ The value of MMP-1, MMP-3, TIMP-1, IL-1 and TNF-α in the synovia was higher than that in the serum (all P〈0.05), while the value of TGF-β was lower than that in the serum (P〈0.05). Conclusion The value of MMP-1, MMP-3, IL-I and TNF-α increases both in the serum and synovia, while the value of TIMP-1 decreases. The value of TGF-β decreases, which may have protective effect on JIA. The ratio of MMP-3/FIMP-1 in the serum is positively correlated to inflammation parameters, which may be used to judge the activity of illness in JIA.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2013年第9期601-605,共5页 Chinese Journal of Rheumatology
基金 武汉市卫生局临床重点专科研究项目(武卫[2007]43号)
关键词 关节炎 幼年型类风湿 间质胶原酶 基质溶解素1 金属蛋白酶类组织抑制剂 白细胞介素1 肿瘤坏死因子α 转化生长因子β Arthritis, juvenile rheumatoid Interstitial collagenase Stromelysin 1 Tissue inhi-bitor of metalloproteinases Interleukin-1 Tumor necrosis factor-alpha Transforming growth factor beta
  • 相关文献

参考文献18

  • 1Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idio- pathic arthritis: second revision, Edmonton. J Rheumatol, 2004, 31 : 390-392.
  • 2Phelan J, Thompson S. Genomic progress in pediatric arthritis: recent work and future goals. Curt Opin Rheumatol, 2006, 18: 482-489. matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid.
  • 3Viswanath V, Myles A, Dayal R, et al. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthe- sitis-related arthritis category of juvenile idiopathic arthritis. J Rheumatol, 2011, 38: 2482-2487.
  • 4Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am, 2012, 59: 301-327.
  • 5Spirchez M, Samasca G, Iancu M, et al. Relation of interleukin- 6, TNF-alpha and interleukin-1 alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab, 2012, 58 : 253-260.
  • 6Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature, 2005, 434: 648-652.
  • 7Mamehara A, Sugimoto T, Sugiyama D, et al. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti- rheumatic drugs. Kobe J Med Sci, 2010, 56: E98-107.
  • 8Ye S, Patodi N, Walker-Bone K, et al. Variation in the matrix metallopruteinase-3,-7,-12 and -13 genes is associated with functional status in rheumatoid arthritis. Int J Immunogenet, 2007, 34: 81-85.
  • 9Wu SQ, Otero M, Unger FM, et al. Anti-inflammatory activity of an ethanolic Caesalpinia sappan extract in human chondrocytes and maerophages. J Ethnopharmaeol, 2011, 138: 364-372.
  • 10Rooncy T, Roux-Lombard P, Veale DJ, et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographie progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis, 2010, 69: 706-714.

二级参考文献10

  • 1胡大伟,鲍春德,陈顺乐,古洁若,栗占国,孙凌云,韩星海,倪立青.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎双盲随机多中心对照临床研究[J].中华风湿病学杂志,2005,9(11):664-668. 被引量:86
  • 2van RPL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis, 2006, 65: 1478-1483.
  • 3Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med, 2002, 346: 1349-1356.
  • 4Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum, 2003, 48: 2122- 2217.
  • 5Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol, 2005, 32: 1232-1242.
  • 6O'Dell JR, Petersen K, Left R, et al. Etanercept in combination with sulfasalazine, hydr.oxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol, 2006, 33: 213-218.
  • 7Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol, 2006, 33: 234-243.
  • 8Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford), 2007, 46: 1122-1125.
  • 9Davis JC Jr, der Heijde DM v, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis, 2008, 67: 346-352.
  • 10Klareskog L, Gaubitz M, Rodfiguez-Valverde V, et al. A longterm, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other diseasemodifying antirheumatic drugs, Ann Rheum Dis, 2006, 65: 1578-1584.

共引文献12

同被引文献98

  • 1李先安,吕国华,李康华.基质金属蛋白酶-1、3与椎间盘退变突出的关系[J].湘南学院学报(自然科学版),2005,7(3):69-72. 被引量:6
  • 2裴建中,张国初.推拿配合扶他林乳胶剂治疗膝骨关节炎50例[J].江苏中医药,2007,39(2):46-46. 被引量:5
  • 3RAVELLI A, MARTINI A. Juvenile idiopathic arthritis[ J].Lancet,2007,369(9563) :767-778.
  • 4MINDEN K, NIEWERTH M, ZINK A, et al. Long-termoutcome of patients with JIA treated with etanercept,resultsof the biologic register JuMBO [ J ]. Rheumatology(Oxford) ,2012,51(8) : 1407-1415.
  • 5BRACAGLIA C, BUONUOMO P S, TOZZI A E,et al.Safety and efficacy of etanercept in a cohort of patients withjuvenile idiopathic arthritis under 4 years of age [ J ]. JRheumatol ,2012,39(6) : 1287-1290.
  • 6UNGAR W J, COSTA V,HANCOCK-HOWARD R, et al.Cost-effectiveness of biologies in polyarticular-coursejuvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs [ J ]. Arthritis Care Res(Hoboken) ,2011,63( 1) ; 111-119.
  • 7PAPSDORF V,HORNEFF G. Complete control of diseaseactivity and remission induced by treatment with etanerceptin juvenile idiopathic arthritis [ J ]. Rheumatology ( Oxford),2011, 50(1) :214-221.
  • 8PRINCE F H, DE BEKKER-GROB E W,TWILT M, et,al. An analysis of the costs and treatment success ofetanercept in juvenile idiopathic arthritis: results from thedutch arthritis and biologicals in children register [ J ].Rheumatology( Oxford),2011 ,50(6) :1131-1136.
  • 9LOVELL D J, REIFF A, ILOWITE N T,et al. Safety andefficacy of up to eight years of continuous etanercept therapyin patients with juvenile rheumatoid arthritis [ J ]. ArthritsRheum,2008 ,58(5) : 1496-1504.
  • 10KERENSKY T A, GOTTLIEB A B, YANIV S, et al.Etanercept : efficacy and safety for approved indications[J].Exp Opin Drug Saf ,2012 ,11 ( 1 ) ; 121 -139.

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部